NCT05180097 - Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions

Hodgkin Lymphoma

Interventions

DRUG

Gemcitabine

1000mg/m2 IV, 30 mins D1, D8

DRUG

Dexamethasone

40mg daily PO, D1-D4

DRUG

Cisplatin

75mg/m2 IV, 1 hour, D1

DRUG

Brentuximab vedotin

1.8 mg/kg IV, 30 mins, Q21 days

DRUG

Pembrolizumab

200mg IV, 30 mins, Q 21 days

Trial Locations (18)

2139

RECRUITING

Concord Repatriation General Hospital, Concord

2500

RECRUITING

Wollongong Hospital, Wollongong

2541

RECRUITING

Shoalhaven Cancer Care Centre, Nowra

3084

RECRUITING

Austin Hospital, Heidelberg

5000

RECRUITING

Royal Adelaide Hospital, Adelaide

6009

RECRUITING

Sir Charles Gairdner Hospital, Perth

T2N 5G2

RECRUITING

Arthur J.E. Child Comprehensive Cancer Centre, Calgary

V5Z 4E6

RECRUITING

BCCA - Vancouver, Vancouver

A1B 3V6

RECRUITING

Dr. H. Bliss Murphy Cancer Centre, St. John's

B3H 1V7

RECRUITING

QEII Health Sciences Centre, Halifax

L8V 5C2

RECRUITING

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

N6A 5W9

RECRUITING

London Health Sciences Centre Research Inc., London

K1H 8L6

RECRUITING

Ottawa Hospital Research Institute, Ottawa

M5G 2M9

RECRUITING

University Health Network, Toronto

H3T 1E2

RECRUITING

The Jewish General Hospital, Montreal

H4A 3J1

RECRUITING

The Research Institute of the McGill University, Montreal

J1H 5N4

RECRUITING

CIUSSS de l'Estrie - Centre hospitalier, Sherbrooke

S4T 7T1

RECRUITING

Allan Blair Cancer Centre, Regina